Therapeutic options in a patient with highly aggressive multiple sclerosis and genetic predisposition to autoimmune process: a clinical case

T. V. Baidina; T. N. Trushnikova; I. Yu. Danchenko

doi:10.17816/pmj406120-127

Perm Medical Journal ›› 2023, Vol. 40 ›› Issue (6) :120 -127. DOI: 10.17816/pmj406120-127

Clinical case

research-article

Therapeutic options in a patient with highly aggressive multiple sclerosis and genetic predisposition to autoimmune process: a clinical case

Author information +

History +

PDF

Abstract

A clinical case of highly aggressive multiple sclerosis in a patient with a family history of demyelinating disease is presented. The effectiveness of early pathogenetic therapy by blocking the adhesion molecules of lymphocytes is demonstrated.

Keywords

highly aggressive multiple sclerosis / demyelination / induction treatment strategy / natalizumab

Cite this article

Download citation ▾

T. V. Baidina, T. N. Trushnikova, I. Yu. Danchenko. Therapeutic options in a patient with highly aggressive multiple sclerosis and genetic predisposition to autoimmune process: a clinical case. Perm Medical Journal, 2023, 40(6): 120-127 DOI:10.17816/pmj406120-127

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Rasseyannyj skleroz u vzroslyh i detej: Proekt klinicheskih rekomendacij. 2020, available at: https://mapcms.ru/upload/iblock/a0f/a0f94b14685f83883eb1b7e90bd8cd95.pdf (in Russian).

[2]	Рассеянный склероз у взрослых и детей: Проект клинических рекомендаций. 2020, available at: https://mapcms.ru/upload/iblock/ a0f/a0f94b14685f83883eb1b7e90bd8cd95.pdf.

[3]	Kasatkin D.S., Spirin N.N. Rasseyannyj skleroz v fokuse. Prikladnoe rukovodstvo. Moscow: Prakticheskaya medicina 2020 (in Russian).

[4]	Касаткин Д.С., Спирин Н.Н. Рассеянный склероз в фокусе. Прикладное руководство. М.: Практическая медицина 2020.

[5]	Díaz C., Zarco L.A., Rivera D.M. Highly active multiple sclerosis: An update. Mult Scler Relat Disord. 2019 May; 30: 215–224. DOI: 10.1016/ j.msard.2019.01.039. Epub 2019. PMID: 30822617.

[6]	Díaz C., Zarco L.A., Rivera D.M. Highly active multiple sclerosis: An update. Mult Scler Relat Disord. 2019; 30: 215–224. DOI: 10.1016/ j.msard.2019.01.039. Epub 2019. PMID: 30822617.

[7]

Arrambide G., Iacobaeus E., Amato M.P., Derfuss T., Vukusic S., Hemmer B., Brundin L., Tintore M. 2018 ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (2): Treatment. Mult Scler. 2020; 26 (9): 1352458520924595. DOI: 10.1177/1352458520924595. Epub ahead of print. PMID: 32530366; PMCID: PMC7412878.

[8]

Iacobaeus E., Arrambide G., Amato M.P., Derfuss T., Vukusic S., Hemmer B., Tintore M., Brundin L. 2018 ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Mult Scler. 2020; 26 (9): 1352458520925369. DOI: 10.1177/ 1352458520925369. Epub ahead of print. PMID: 32530385; PMCID: PMC7412876.

[9]	Bowen J.D. Highly Aggressive Multiple Sclerosis. Continuum (Minneap Minn). 2019; 25 (3): 689–714. DOI: 10.1212/CON.0000000000000731. PMID: 31162312.

[10]

Davydovskaya M.V., Hachanova N.V., Evdoshenko E.P., Pronin I.N., Bojko A.N., Zaharova M.N., Alifirova V.M., Turova E.A., Malkova N.A., Siverceva S.A., Cukurova L.A., Skoromec A.A., Solodun I.YU. Rekomendacii po algoritmu vybora preparata i planu upravleniya riskami terapii Natalizumabom u pacientov s remittiruyushchim rasseyannym sklerozom. Moscow 2018 (in Russian).

[11]

Давыдовская М.В., Хачанова Н.В., Евдошенко Е.П., Пронин И.Н., Бойко А.Н., Захарова М.Н., Алифирова В.М., Турова Е.А., Малкова Н.А., Сиверцева С.А., Цукурова Л.А., Скоромец А.А., Солодун И.Ю. Рекомендации по алгоритму выбора препарата и плану управления рисками терапии натализумабом у пациентов с ремиттирующим рассеянным склерозом. М. 2018.

[12]	Khoy K., Mariotte D., Defer G., Petit G., Toutirais O., Le Mauff B. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020; 11: 549842. DOI: 10.3389/fimmu.2020.549842. PMID: 33072089; PMCID: PMC7541830.

[13]	Khachanova N.V. Vysokoaktivnyĭ rasseiannyĭ skleroz – vozmozhnosti vybora terapii monoklonal'nymi antitelami. Zh Nevrol Psikhiatr Im S.S. Korsakova 2019; 119: 49–57. DOI: 10.17116/jnevro20191191049. PMID: 3193498.

[14]	Хачанова Н.В. Высокоактивный рассеянный склероз – возможности выбора терапии моноклональными антителами. Журнал неврологии и психиатрии им. С.С. Корсакова 2019; 119: 49–57. DOI: 10.17116/jnevro 20191191049. PMID: 3193498.

[15]	Parks N.E., Flanagan E.P., Lucchinetti C.F., Wingerchuk D.M. NEDA treatment target? No evident disease activity as an actionable outcome in practice. J Neurol Sci. 2017; 383: 31–34. DOI: 10.1016/j.jns.2017.10.015.

[16]

Zheng C., Kar I., Chen C.K., Sau C., Woodson S., Serra A., Abboud H. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020; 34 (9): 879–896. DOI: 10.1007/s40263-020-00756-y. PMID: 32780300; PMCID: PMC7417850.